Analysis of patent applications relating to peroxisome proliferator-activated receptor (PPAR) ligands in 2004

Bibliography

• BANNER CD, GOTTLICHER M, WIDMARK E, SJOVALL J, RAFTER JJ, GUSTAFSSON JA: A systematic analytical chemistry/cell assay approach to isolate activators of orphan nuclear receptors from biological extracts: characterization of peroxisome proliferator-activated receptor activator in plasmas. J. Lipid Res. (1993) 34(9):1583–1591.
   PubMed Web of Science ®Google Scholar
• MANGELSDORF DJ, EVANS RM: The RXR heterodimers and orphan receptors. Cell (1995) 83(6):841–850.
   PubMed Web of Science ®Google Scholar
• NUCLEAR RECEPTOR NOMENCLATURE COMMITTEE: A unified nomenclature system for the nuclear receptor superfamily. Cell (1999) 97(2):161–163.
   PubMed Web of Science ®Google Scholar
• WILLSON TM, BROWN PJ, STERNBACH DD, HENKE BR: The PPARs: from orphan receptors to drug discovery. J. Med. Chem. (2000) 43(4):527–550.
   PubMed Web of Science ®Google Scholar
• •Excellent review on PPAR ligands and molecular pharmacology.
   Google Scholar
• KLIEWER SA, UMESONO K, NOONAN DJ, HEYMAN RA, EVANS RM: Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature (1992) 358(6389):771–774.
   PubMed Web of Science ®Google Scholar
• KELLER H, DREYER C, MEDIN J, MAHFOUDI A. OZATO K, WAHLI W: Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl Acad. Sci. USA (1993) 90(61:2160–2164.
   PubMed Web of Science ®Google Scholar
• OKUNO A. TAMEMOTO H, TOBE K et al.: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. Clin . Invest. (1998) 101(61:1354–1361.
   Google Scholar
• YAMAUCHI T, KAMON J, WAKI H: The mechanisms by which both heterozygous peroxisome proliferator-activated receptor y (PPARy) deficiency and PPARy agonist improve insulin resistance. J. Biol Chem. (2001) 276(44):41245–41254.
   PubMed Web of Science ®Google Scholar
• MOMOSE Y, MEGURO K, IKEDA H,HATANAKA C, OI S, SOHDA T: Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds. Chem. Pharm. Bul. (1991) 39(6):1440–1445.
   Google Scholar
• CANTELLO BC, CAWTHORNE MA, COTTAM GP et al.: [[Omega-(heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem. (1994) 37(23):3977–3985.
   PubMed Web of Science ®Google Scholar
• LEHMANN JM, MOORE LB, SMITH-OLIVER TA et al.: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor y (PPARy). Biol. Chem (1995) 270:12953–12956.
   Web of Science ®Google Scholar
• STAELS B, AUWERX J: Role of PPAR inthe pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones. Curr. Pharmaceut. Des. (1997) 3(1):1–14.
   Web of Science ®Google Scholar
• LINTON MF, FAZIO S: Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk. Curr. Atheroscler. Rep. (2000) 2(1):29–35.
   PubMedGoogle Scholar
• FORMAN BM, CHEN J, EVANS RM: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors a and 8. Proc. Natl. Acad. Sci. USA (1997) 94(9):4312–4317.
   PubMed Web of Science ®Google Scholar
• BROWN PJ, WINEGAR DA. PLUNKET KD et al.: A ureido-thiobutyric acid (GW9578) is a subtype-selective PPARa agonist with potent lipid-lowering activity. J. Med. Chem. (1999) 42(19):3785–3788.
   Google Scholar
• •First disclosure of phenoxyacetic acid type PPARa selective agonist.
   Google Scholar
• BROWN PJ, STUART LW, HURLEY KP et al.: Identification of a subtype selective human PPARa agonist through parallel-array synthesis. Bioorg-. Med. Chem. Lett (2001) 11(9):1225–1227.
   PubMed Web of Science ®Google Scholar
• XU Y, MAYHUGH D, SAEED A: Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor a agonist. J. Med. Chem (2003) 46(24): 5121–5124.
   PubMed Web of Science ®Google Scholar
• MIYACHI H, NOMURA M, TANASE T et al: Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor (PPAR) activators: novel human PPARa-selective activators. Bioorg Med. Chem. Lett. (2002) 12(1):77–80.
   PubMed Web of Science ®Google Scholar
• MIYACHI H, NOMURA M, TANASE T, SUZUKI M, MURAKAMI K, AWANO K: Enantio-dependent binding and transactivation of optically active phenylpropanoic acid derivatives at human peroxisome proliferator-activated receptor alpha. Bioorg-. Med. Chem. Lett. (2002) 12(3):333–335.
   PubMed Web of Science ®Google Scholar
• NOMURA M, TANASE T, MIYACHI H: Efficient asymmetric synthesis of (S)-2-ethylphenylpropanoic acid derivative, a selective agonist for human peroxisome proliferator-activated receptor a. Bioorg-. Med. Chem. Lett. (2002) 12(16):2101–2104.
   PubMed Web of Science ®Google Scholar
• NOMURA M, TANASE T, IDE T et al: Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor a subtype-selective activators. J. Med. Chem. (2003) 46(17):3581–3599.
   Google Scholar
• SUGIYAMA Y, AOKI T, ASAKI T et al: A novel 1,3-dioxane-2-carboxylic acid derivatives, NS-220, as a highly potent and selective PPARa agonist. A/MECS03, Kyoto, Japan (2003) B22.
   Google Scholar
• PILL J, KUHNLE HF: BM 17.0744: a structurally new antidiabetic compound with insulin-sensitizing and lipid-lowering activity. Metabolism (1999) 48(1):34–40.
   Google Scholar
• LIM H, GUPTA RA, MA WG et ell.: Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPAR8. Genes Dev. (1999) 13(12):1561–1574.
   Google Scholar
• BERGER J, LEIBOWITZ MD, DOEBBER TW et al.: Novel peroxisome proliferator-activated receptor (PPAR)y and PPAR8 ligands produce distinct biological effects. J. Biol. Chem. (1999) 274(106718–6725.
   Web of Science ®Google Scholar
• SCHMUTH M, HAQQ CM, CAIRNS WJ et al.: Peroxisome proliferator-activated receptor (PPAR)-13/8 stimulates differentiation and lipid accumulation in keratinocytes. J. Invest. Dermatol (2004) 122(0971–983.
   PubMed Web of Science ®Google Scholar
• BARAK Y, LIAO D, HE Wet al.: Effects of peroxisome proliferator-activated receptor 8 on placentation, adiposity, and colorectal cancer. Proc. Natl Acad. Sci. USA (2002) 99(1):303–308.
   Google Scholar
• SZNAIDMAN ML, HAFFNER CD, MALONEY PR et al.: Novel selective small molecule agonists for peroxisome proliferator-activated receptor 8 (PPAR8)-synthesis and biological activity. Bioorg Med. Chem. Lett. (2003) 13(9):1517–1521.
   PubMed Web of Science ®Google Scholar
• LUDVIK B: Diabetes therapy related to etiology. Indications, uses and side effects of new insulin sensitizers. MMW Fortschr Med. (2000) 142(28-29):27–28.
   PubMedGoogle Scholar
• RZONCA SO, SUVA LJ, GADDY D, MONTAGUE DC, LECKA-CZERNIK B: Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology (2004) 45(1):401–406.
   Google Scholar
• PANZ VR, WING JR, RAAL FJ, KEDDA MA, JOFFE BI: Improved glucose tolerance after effective lipid-lowering therapy with bezafibrate in a patient with lipoatrophic diabetes mellitus: a putative role for Randle's cycle in its pathogenesis? Clin. Endocrinol (1997) 46(3):365–368.
   Web of Science ®Google Scholar
• HENKE B: Peroxisome proliferator-activated receptor a/y dual agonists for the treatment of Type 2 diabetes. J. Med. Chem. (2004) 47(17):4118–4127.
   PubMed Web of Science ®Google Scholar
• MURAKAMI K, TOBE K, IDE T et al: A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor a (PPAR a) and PPARy: effect of PPAR-a activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes. (1998) 47(12):1841–1847.
   PubMed Web of Science ®Google Scholar
• NOMURA M, KINOSHITA S, SATOH H et al.: (3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents. Bioorg-. Med. Chem. Lett. (1999) 9(0533–538.
   PubMed Web of Science ®Google Scholar
• LJUNG B, BAMBERG K, DAHLLOF B et al.: AZ 242, a novel PPARa/y agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J. Lipid Res. (2002) 43(11):1855–1863.
   PubMed Web of Science ®Google Scholar
• CRONET P, PETERSEN JF, FOLMER R et al.: Structure of the PPARa and y ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure (2001) 9(0699–706.
   PubMed Web of Science ®Google Scholar
• LOHRAY BB, LOHRAY VB, BAJJI AC et al.: (-)344-[2-(Phenoxazin-10-ypethoxy[pheny11-2-ethoxypropanoic acid [(-)DRE 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J. Med. Chem. (2001) 44(16): 2675–2678.
   PubMed Web of Science ®Google Scholar
• MILLER AR, ETGEN GJ: Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome. Expert Opin. Invest!' g: Drugs (2003) 12(9):1489–1500.
   PubMed Web of Science ®Google Scholar
• BROOKS DA, ETGEN GJ, RITO CJ et al.: Design and synthesis of 2-methy1-2-[4-(2-[5-methy1-2-aryloxazol-4-yhethoxy)phenoxy[propionic acids: a new class of dual PPARa/y agonists. J. Med. Chem. (2001) 44(13):2061–2064.
   PubMed Web of Science ®Google Scholar
• DEVASTHALE PV, CHEN S, JEON Y et al: Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-pheny1-4-oxazolypethoxy[phenyllmethyl[glycine [muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor a/y dual agonist with efficacious glucose and lipid-lowering activities. J. Med. Chem. (2005) 48(6):2248–2250.
   PubMed Web of Science ®Google Scholar
• DESAI RC, HAN W, METZGER EJ et al: 5-Aryl thiazolidine-2,4-diones: discovery of PPAR dual a/y agonists as antidiabetic agents. Bioorg-. Med. Chem. Lett. (2003) 13(10:2795–2798.
   PubMed Web of Science ®Google Scholar
• ADAMS AD, YUEN W, HU Z et al.: Amphipathic 3-pheny1-7-propylbenzisoxazoles; human PPARy, 8 and a agonists. Bioorg. Med. Chem. Lett. (2003) 13(5):931–935.
   PubMed Web of Science ®Google Scholar
• SOHDA T, MIZUNO K, TAWADA H, SUGIYAMA Y, FUJITA T, KAWAMATSU Y: Studies on antidiabetic agents. I. Synthesis of 544-(2-methy1-2-phenylpropoxy)-benzyllthiazolidine-2,4-dione (AL-321) and related compounds. Chem. Pharm. Bull. (1982) 30(10):3563–3573.
   Google Scholar
• BERGER JP, PETRO AE, MACNAUL KL et al.: Distinct properties and advantages of a novel peroxisome proliferator-activated protein ly1 selective modulator. MoL EndocrinoL (2003) 17(4):662–676.
   PubMedGoogle Scholar
• ROCCHI S, PICARD F, VAMECQJ et al.: A unique PPARy ligand with potent insulin-sensitizing yet weak adipogenic activity. MoL Cell. (2001) 8(4):737–747.
   PubMed Web of Science ®Google Scholar
• SHIMAYA A, KUROSAKI E, NAKANO R, HIRAYAMA R, SHIBASAKI M, SHIKAMA H: The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice. Metabolism (2000) 49(3):411–417.
   PubMed Web of Science ®Google Scholar
• OBERFIELD JL, COLLINS JL, HOLMES CP et al.: A peroxisome proliferator-activated receptor y ligand inhibits adipocyte differentiation. Proc. Nail. Acad. Sci. USA (1999) 96(1 0:6102–6106.
   Google Scholar